These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 4624276

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/British Medical Research Council.
    Am Rev Respir Dis; 1991 Apr; 143(4 Pt 1):700-6. PubMed ID: 1901199
    [Abstract] [Full Text] [Related]

  • 23. Primary isoniazid-resistant tuberculosis in children. Clinical features, strain resistance, treatment, and outcome in 26 children treated at Kings County Medical Center of Brooklyn between the years 1961 and 1972.
    Steiner P, Rao M, Victoria M, Steiner M.
    Am Rev Respir Dis; 1974 Sep; 110(3):306-11. PubMed ID: 4213311
    [No Abstract] [Full Text] [Related]

  • 24. Controlled therapeutic trial with the combination rifampicin-isoniazid given for six months to previously untreated patients with pulmonary tuberculosis.
    Dubra F.
    Bull Int Union Tuberc; 1972 Feb; 47():37-40. PubMed ID: 4562016
    [No Abstract] [Full Text] [Related]

  • 25. Correlation of in vitro and in vivo kinetics with clinical use of isoniazid, ethambutol, and rifampin.
    Jenne JW, Beggs WH.
    Am Rev Respir Dis; 1973 Jun; 107(6):1013-21. PubMed ID: 4197230
    [No Abstract] [Full Text] [Related]

  • 26. Daily and intermittent short-course regimens in the original treatment of pulmonary tuberculosis. Preliminary results. Cooperative comparative clinical study in Poland.
    Zierski M.
    Scand J Respir Dis Suppl; 1978 Jun; 102():48-52. PubMed ID: 278215
    [No Abstract] [Full Text] [Related]

  • 27. The Australian rifampicin trial.
    Proust A, Evans C.
    Med J Aust; 1972 Oct 14; 2(16):861-7. PubMed ID: 4647286
    [No Abstract] [Full Text] [Related]

  • 28. Treatment of isoniazid-resistant pulmonary tuberculosis with ethambutol, rifampicin and capreomycin: a co-operative study in England and Wales.
    Andrews RH, Jenkins PA, Marks J, Pines A, Selkon JB, Somner AR.
    Tubercle; 1974 Jun 14; 55(2):105-13. PubMed ID: 4143450
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Results of 6-month and 9-month treatments with rifampin, isoniazid and ethambutol in cases of newly detected tuberculosis].
    Szymanski A, Gaik A.
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1981 Jun 14; 30(3):181-3. PubMed ID: 6273991
    [No Abstract] [Full Text] [Related]

  • 33. Exogenous reinfection with Mycobacterium tuberculosis confirmed by phage typing.
    Raleigh JW, Wichelhausen R.
    Am Rev Respir Dis; 1973 Sep 14; 108(3):639-42. PubMed ID: 4200815
    [No Abstract] [Full Text] [Related]

  • 34. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association.
    Lancet; 1975 Jan 18; 1(7899):119-24. PubMed ID: 46047
    [Abstract] [Full Text] [Related]

  • 35. Antituberculosis activity of rifampin. Report of studies performed and in progress (1966-1971).
    Nitti V.
    Chest; 1972 Jun 18; 61(6):589-98. PubMed ID: 4624281
    [No Abstract] [Full Text] [Related]

  • 36. [Place of bacteriological examination in the treatment of tuberculosis].
    Gyselen A.
    Acta Tuberc Pneumol Belg; 1972 Jun 18; 63(4):405-8. PubMed ID: 4206438
    [No Abstract] [Full Text] [Related]

  • 37. Two excellent management tools for national tuberculosis programmes: history of prior treatment and sputum status at two months.
    Trébucq A, Rieder HL.
    Int J Tuberc Lung Dis; 1998 Mar 18; 2(3):184-6. PubMed ID: 9526189
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The effect of acceptable and adequate outpatient treatment on the length of hospitalization and on readmission for relapse or reactivation of pulmonary tuberculosis.
    Curry FJ.
    Chest; 1973 Apr 18; 63(4):536-46. PubMed ID: 4633013
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.